Q3 EPS Estimates for GeoVax Labs Boosted by Noble Financial

GeoVax Labs Inc. (NASDAQ:GOVX) – Research analysts at Noble Financial lifted their Q3 2026 earnings per share estimates for shares of GeoVax Labs in a note issued to investors on Wednesday, July 29th. Noble Financial analyst R. Leboyer now forecasts that the company will post earnings per share of ($1.09) for the quarter, up from their prior estimate of ($3.28). The consensus estimate for GeoVax Labs’ current full-year earnings is ($8.69) per share. Noble Financial also issued estimates for GeoVax Labs’ Q4 2026 earnings at ($1.20) EPS, FY2026 earnings at ($5.14) EPS and FY2027 earnings at ($2.64) EPS.

A number of other equities analysts have also recently commented on GOVX. Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a research note on Friday, July 17th. D. Boral Capital reaffirmed a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. Finally, Wall Street Zen upgraded shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research report on Sunday, June 21st. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, GeoVax Labs currently has a consensus rating of “Reduce” and an average target price of $150.00.

GeoVax Labs Price Performance

Shares of GOVX opened at $0.69 on Friday. GeoVax Labs has a 1-year low of $0.64 and a 1-year high of $20.00. The company has a market capitalization of $2.41 million, a P/E ratio of -0.04 and a beta of 3.68. The firm’s 50 day simple moving average is $1.43 and its 200 day simple moving average is $1.74.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings data on Monday, July 27th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($2.16) by $1.19.

Institutional Trading of GeoVax Labs

Several hedge funds and other institutional investors have recently bought and sold shares of GOVX. Jane Street Group LLC purchased a new stake in GeoVax Labs in the fourth quarter worth approximately $99,000. HRT Financial LP purchased a new position in shares of GeoVax Labs during the fourth quarter worth approximately $31,000. Renaissance Technologies LLC bought a new stake in shares of GeoVax Labs in the 4th quarter worth approximately $104,000. Finally, Armistice Capital LLC bought a new stake in shares of GeoVax Labs in the 3rd quarter worth approximately $253,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.